Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
Authors/Creators
- 1. University of California, Berkeley
- 2. University Hospital of Basel
- 3. McGill University
- 4. University of Pennsylvania
- 5. Centre Hospitalier Universitaire de Bordeaux
- 6. Washington University in St. Louis School of Medicine
- 7. University of British Columbia
- 8. The University of Texas Health Science Center at Houston
- 9. Roche (Switzerland)
- 10. Genetec (United States)
- 11. University of Toronto
Description
Objective
To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA studies in relapsing multiple sclerosis.
Methods
After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN) β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression/improvement (CDP/CDI), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.
Results
Of patients entering the OLE phase, 88.6% completed Year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier, vs patients initially receiving IFN β-1a (16.1% vs 21.3% at Year 5; p=0.014). Patients continuing OCR maintained, and those switching from IFN β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from Year 3 to 5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN β-1a (–1.87% vs –2.15% at Year 5; p<0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.
Conclusion
Compared with patients switching from IFN β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.
Notes
Funding provided by: F. Hoffmann-La Roche
Crossref Funder Registry ID: http://dx.doi.org/10.13039/100007013
Award Number:
Files
Figure_e-1.pdf
Files
(829.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:4fbeace418cc625e207d91b4f37bd572
|
274.0 kB | Preview Download |
|
md5:ba60a500a2b3b6535102a16e03c9e709
|
181.7 kB | Preview Download |
|
md5:b29dd3637a063d7647083ce595d98729
|
78.7 kB | Preview Download |
|
md5:9d1aeaa5a9dd8195486f916b8c2a64a0
|
168.5 kB | Preview Download |
|
md5:1de87942767392b5cdbea5e9f029beb5
|
126.5 kB | Preview Download |
Additional details
Related works
- Is cited by
- 10.1056/NEJMoa1601277 (DOI)